Autologous anti-CD19 chimeric antigen receptor T (CAR-T19) cell drugs have been approved to treat relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (B-ALL) in patients up to 25 years old in the USA and Europe [1]. This evidence concerns the gene CD19 and B-cell acute lymphoblastic leukemia.